BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:U.S. CDMRP – Lung Cancer Research Program | Research Funding
DTSTART;VALUE=DATE:20260623
DTSTAMP:20260528T052255Z
UID:bb7d40c6fb29462ac57cd7f83a17997e6b0c11e356d44bb4c1269032
CATEGORIES:Call for proposal
DESCRIPTION:Aim: Through the Congressionally Directed Medical Research Pro
 gram (CDMRP)\, the Department of Defense is announcing the 2026 Lung Cance
 r Research Program (LCRP) Awards. Several award programs are available:\n\
 n	The Idea Development Award Supports new ideas in the early stages of dev
 elopment representing innovative\, high-risk/high-gain research.\n	The Pat
 ient-Centered Outcomes and Survivorship Award Supports advanced translatio
 nal research that will foster transformation of promising ideas in lung ca
 ncer into clinical applications.\n	The Translational Research Award mechan
 ism supports advanced translational research that will foster transformati
 on of promising ideas in lung cancer into clinical applications. Translati
 onal research may be defined as an integration of basic science and clinic
 al observations. Observations that drive a research idea may originate fro
 m a laboratory discovery\, population-based studies\, or a clinician’s f
 irsthand knowledge of patient care. The ultimate goal of translational res
 earch is to move a concept or observation forward into clinical applicatio
 n.\n\nAll applications for LCRP funding must specifically address at least
  one of the Areas of Emphasis. The FY26 LCRP Areas are listed at the end o
 f this announcement.\n\nFunding:      \nIdea Development Award: max. 
 $800K\nPatient-Centered Outcomes and Survivorship Award: max. $975K\nTrans
 lational Research Award: $1.35M – $1.85M\nNote: Cost caps are total cos
 ts (direct plus indirect costs). In accordance with EPFL guidelines\, bud
 gets should include a 20% overhead\, and the total budget must remain with
 in the grant’s maximum allowable funding\n\nDuration:   \nIdea Develop
 ment Award: 3 years\nPatient-Centered Outcomes and Survivorship Award: 3 y
 ears\nTranslational Research Award: 3-4 years\n\nEligibility: Applicants f
 rom international organizations or institutions are eligible to apply\, an
 d there are no citizenship restrictions. Program-specific seniority levels
  and eligibility criteria are further defined within each award mechanism 
 here.\n\nHow to Apply: Pre-applications are submitted through the eBRAP pl
 atform. They should contain contact information\, a letter of intent\, and
  a list of collaborators and key personnel as suggested on the platform. F
 ull applications will be made via a Grants.gov workspace.\n\nPre-Applicati
 on Deadline:          \n\n\n	23 June 2026\, 5:00 p.m. Eastern time\n
 \n	\n		Idea Development Award\n		Translational Research Award\n	\n	\n	18 A
 ugust 2026\, 5:00 p.m. Eastern time\n	\n		Patient-Centered Outcomes and Su
 rvivorship Award\n	\n	\n\nFull Application Deadline for all calls:\n\n\n	0
 2 September 2026\, 11:59 p.m Eastern Time\n\n         \nFurther infor
 mation:\n\n\n	To find the full program announcements and to start your pre
 -application see here\n	A useful summary of each call can be found here\n	
 For questions about the eBRAP or Grants.gov platforms\, contact the Resear
 ch Office\n	Grants.gov Funding Opportunity Numbers:\n	\n		Idea Development
  Award: HT942526LCRPIDA\n		Patient-Centered Outcomes and Survivorship Awar
 d: HT942526LCRPPCOSA\n		Translational Research Award: HT942526LCRPTRA\n	\n
 	\n\n\nFY26 LCRP Areas of Emphasis\n\n\n	Biology and Etiology\n	\n		Unders
 tand the molecular mechanisms of initiation and progression of pre-maligna
 ncy to lung cancer.\n		Understand contributors to lung cancer development 
 other than tobacco\, including hereditary and sex-specific differences.\n	
 	Understand the biology of metastatic/oligometastatic disease progression.
 \n	\n	\n	Prevention and Risk Reduction\n	\n		Identify innovative strategie
 s for the prevention and/or interception of lung cancer development.\n		Id
 entify innovative strategies for the prevention of recurrence or metastase
 s from lung cancer.\n	\n	\n	Detection\, Diagnosis and Surveillance\n	\n		I
 mprove and expand approaches to screening and early detection of lung canc
 er.\n		Identify strategies for prompt detection and/or characterization of
  progressive disease.\n	\n	\n	Treatment and Prognosis\n	\n		Identify innov
 ative strategies for the treatment of lung cancer\, including overcoming r
 esistance.\n		Develop or optimize biomarkers to assist with therapeutic de
 cision-making.\n		Enhance the understanding\, detection\, and treatment of
  brain and leptomeningeal metastases in lung cancer.\n	\n	\n	Health Outcom
 es and Survivorship\n	\n		Identify and understand the long-term and cumula
 tive effects of lung cancer and its treatment(s) on quality of life for pa
 tients and families.\n		Identify and understand the impact of comorbiditie
 s on survivorship care in all stages of lung cancer.\n		Reduce differences
  among high-risk groups and populations.\n	\n	\n
LOCATION:
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR